[BioS] CrossPoint Signs MOU with Samyang Biopharm to Develop Anticancer siRNA
Predicted impact: Low
Non-binding MOU for early-stage anticancer siRNA development; no financial terms or revenue size disclosed.
Samyang Biopharm삼양바이오팜
0120G0 · KOSPI · ₩0120G0 · 삼양바이오팜
₩41,550▼ ₩450 (1.07%)End-of-day · Oct 28, 2026 · End-of-day prices.
Price · 1Y +37.58%
- Market cap
- ₩309B
- Enterprise value
- ₩306B
- P/E
- 138.1×
- P/B
- 1.3×
- Dividend yield
- 0.0%
- ROE
- 0.9%
- Net margin
- 7.8%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−72.5% from the high
₩23,250Today: ₩41,400 – ₩43,850₩150,900
Returns
- 1W−9.1%
- 1M−12.2%
- 3M+17.0%
- 6M−46.7%
- YTD−20.9%
- 1Y—
- Volume today
- 25,029
- 0.7× the 20-day average
- Traded today
- ₩1.1B
- Listed shares
- 7,435,870
- EPS (12 months)
- ₩301
- Earnings yield 0.7%
AI researchResearch being writtenOur AI is writing a report on this company from filed data, prices and news. Check back soon.
🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Quiet- BuzzQuietBuzz 42 of 100 (50 is a normal day for this stock).
- SentimentPositiveNews: Partnership news on new drug development is generally positive, though it is an early-stage agreement. Community: 0 bullish, 0 bearish posts this week.
- MomentumWeak-10.6% over the last month; the price is below its 20-day average.
- News impactLow3 news items and filings in two weeks; 0 rated high impact, 0 medium.
Signals describe activity, not recommendations. Not financial advice.
Samyang Biopharm stock overview
Samyang Biopharm (삼양바이오팜, KRX: 0120G0) is listed on KOSPI, in the Biotech & Pharma sector. The company operates in three segments: medical devices, pharmaceuticals, and new drug development. Its shares closed at ₩41,550 on Oct 28, 2026, down 1.07% on the day, giving it a market value of ₩309B.
Key facts
- Market cap
- ₩309B
- Sector
- Biotech & Pharma
- Latest price change
- −1.07%
- As of
- Oct 28, 2026
- Main business
- The company operates in three segments: medical devices, pharmaceuticals, and new drug development.
Quick answers about Samyang Biopharm
- What does Samyang Biopharm do?
- The company operates in three segments: medical devices, pharmaceuticals, and new drug development. Its medical device products include biodegradable surgical sutures and absorbable hemostats, while its pharmaceutical products include solid tumor and blood cancer anticancer drugs. It also conducts R&D on gene therapy drug delivery based on its proprietary SENS platform, and it generates most of its sales from overseas markets.
- What is the market cap of Samyang Biopharm?
- The market capitalisation of Samyang Biopharm was ₩309B at the close on Oct 28, 2026.
- Who are the largest shareholders of Samyang Biopharm?
- According to the latest official filings, the largest reported holders are Kim Yoon (46.41%, as of Aug 10, 2026); Kim Won (5.80%, as of Nov 26, 2025); Kim Jeong (5.21%, as of Nov 26, 2025).
- When is the next earnings report from Samyang Biopharm?
- Korean companies rarely announce results dates in advance. Based on when Samyang Biopharm filed the same report in past years, its next annual results is expected around Mar 13, 2027.
- Does the National Pension Service own Samyang Biopharm?
- Yes. The National Pension Service held 1.73% of Samyang Biopharm shares as of Dec 31, 2025.
Company profile
The company operates in three segments: medical devices, pharmaceuticals, and new drug development. Its medical device products include biodegradable surgical sutures and absorbable hemostats, while its pharmaceutical products include solid tumor and blood cancer anticancer drugs. It also conducts R&D on gene therapy drug delivery based on its proprietary SENS platform, and it generates most of its sales from overseas markets.
Written by AI from the company's latest annual report.
- Korean name
- 삼양바이오팜
- Sector
- Biotech & Pharma
- Themes
- Biotech (new drugs)
- Business group
- Samyang
- CEO
- 김경진
- Founded
- Nov 2025
- Listed
- Nov 2025
- Listed shares
- 7,435,870
- Fiscal year ends
- Month 12
- Website
- www.samyangbiopharm.com
Similar companies
- Samsung Biologics207940 · ₩64T₩1,372,000−0.15%
- Celltrion068270 · ₩44T₩189,800+0.64%
- Alteogen196170 · ₩16T₩223,000+2.06%
- SK biopharmaceuticals326030 · ₩5.9T₩75,200+0.40%
- Yuhan000100 · ₩5.7T₩77,300−3.38%
- HLB028300 · ₩5.4T₩40,650+1.88%
- Hanmi Pharm128940 · ₩4.7T₩369,500+5.42%
- SAM Chun Dang Pharm000250 · ₩4.5T₩190,000+1.28%
Recent news
Samyang Biopharmaceuticals and CrossPoint Co-Develop Next-Generation Targeted Gene Therapy
Predicted impact: Low
Co-development MOU with CrossPoint already reported within the last 14 days.
[BioS] CrossPoint Signs MOU with Samyang Biopharm to Develop Anticancer siRNA
Predicted impact: Low
Non-binding MOU for early-stage anticancer siRNA development; no financial terms or revenue size disclosed.
Recent filings
See all- Disclosure on Large Business Group Status [Quarterly Disclosure (For Individual Company)]Aug 31, 2026
- Half-year report (Jun 2026)Aug 14, 2026
- Matters Concerning Payment Amounts by Payment Method and Payment Period, and Dispute Mediation BodiesAug 14, 2026
- Change in largest shareholder's holdingsAug 10, 2026
- 5%+ holding reportAug 10, 2026
Titles in Korean until English translations are added.
Also known as: Samyang Biopharm / 삼양바이오팜 / 0120G0 / KRX:0120G0
Source: KRX statistical information